Welcome to our dedicated page for Astria Therapeutics news (Ticker: ATXS), a resource for investors and traders seeking the latest updates and insights on Astria Therapeutics stock.
Astria Therapeutics Inc (ATXS) is a biopharmaceutical innovator developing monoclonal antibody therapies for rare immunological conditions like hereditary angioedema and atopic dermatitis. This page aggregates all official company announcements and verified news updates for stakeholders tracking its preclinical pipeline and scientific advancements.
Investors and researchers will find timely updates on clinical developments, regulatory milestones, and strategic partnerships. Our curated feed includes progress reports on key candidates like plasma kallikrein inhibitors and OX40 antagonists, along with analyses of their potential impact on underserved patient populations.
Content spans trial design announcements, patent filings, executive commentary, and peer-reviewed research collaborations. All materials are vetted for accuracy and presented in chronological order to help users track the company's evolving position in the rare disease therapeutics market.
Bookmark this page for streamlined access to ATXS's latest scientific disclosures and corporate developments. Check regularly for updates on antibody engineering breakthroughs and preclinical validation studies shaping the future of immune disorder treatments.
Astria Therapeutics, Inc. (NASDAQ:ATXS) reported financial results for Q1 2024, highlighting the positive proof-of-concept results of STAR-0215 for HAE treatment. The company plans to start Phase 3 trials in Q1 2025 and expand label with Q6M administration. Moreover, Astria is developing STAR-0310 for atopic dermatitis and aims to submit an IND application by 2024. The company also shared corporate updates and financial results.
Astria Therapeutics, a biopharmaceutical company, will be presenting information on STAR-0310 at the Society for Investigative Dermatology Annual Meeting. The presentation will focus on the preclinical profile of a novel OX40 antagonistic monoclonal antibody. Dr. Chunxia Lily Zhao will present the poster at the event in May 2024.
Astria Therapeutics, Inc. (Nasdaq:ATXS) granted stock options to purchase 173,500 shares of common stock under the 2022 Inducement Stock Incentive Plan to new employees. The options have an exercise price of $9.50, vesting over four years, with 25% vesting after one year and the rest monthly over 36 months, contingent on continued employment.
FAQ
What is the current stock price of Astria Therapeutics (ATXS)?
What is the market cap of Astria Therapeutics (ATXS)?
